Beacon Biosignals Partners with Harmony Biosciences to Integrate AI-Driven EEG Technology in Phase 3 Hypersomnia Trials
核心洞察
Beacon Biosignals (搜索) announced a collaboration with Harmony Biosciences to incorporate quantitative EEG measurements into two Phase 3 studies of HBS-301 (搜索) for narcolepsy (搜索) and idiopathic hypersomnia (搜索).
The partnership will use Beacon's FDA 510(k)-cleared Waveband EEG headband to capture objective sleep data alongside traditional patient-reported outcomes like the Epworth Sleepiness Scale.
The collaboration aims to enhance precision in evaluating treatment outcomes for hypersomnia disorders by providing continuous monitoring of both nighttime sleep quality and daytime sleepiness patterns.
Beacon Biosignals (搜索), a leader in AI-driven neurophysiology and precision drug development, announced a collaboration with Harmony Biosciences to incorporate quantitative electroencephalography (EEG) measurements into two Phase 3 studies of HBS-301 (搜索) for narcolepsy (搜索) and idiopathic hypersomnia (搜索). The partnership aims to complement traditional patient-reported outcomes with objective sleep EEG data to assess excessive daytime sleepiness (搜索) (EDS).
Advanced EEG Technology Integration
The collaboration will utilize Beacon's FDA 510(k)-cleared Waveband EEG headband and AI-driven algorithms to capture at-home brain data across consecutive nights of sleep. The wireless, low-profile design enables continuous EEG monitoring to assess both nighttime sleep quality and daytime naps, providing a more precise view of hypersomnolence in real-world environments.
"This collaboration with Harmony represents an important step toward bringing quantitative sleep neurophysiology into late-stage drug development," said David Matthews, PhD, President of Life Sciences at Beacon Biosignals (搜索). "Measuring objective sleep EEG data alongside subjective endpoints like patient-reported outcomes improves the precision and interpretability of treatment outcomes, and we expect it will accelerate the path toward better therapies for people living with hypersomnia disorders."
Addressing Clinical Trial Limitations
Current trial measures for hypersomnia conditions rely heavily on subjective patient-reported scales, such as the Epworth Sleepiness Scale (ESS), which may underrepresent the true burden of disease. Narcolepsy (搜索) is characterized by severe excessive daytime sleepiness (搜索) with or without cataplexy (搜索), while idiopathic hypersomnia (搜索) presents with debilitating EDS, prolonged unrefreshing naps, and severe sleep inertia (搜索) following nighttime sleep.
The addition of quantitative EEG-based endpoints allows for more robust characterization of both daytime and nighttime sleep patterns, enabling identification of EEG biomarkers that may inform dose selection, efficacy assessment, and potential patient subgroup analysis.
Clinical Development Impact
Kumar Budur, MD, MS, Chief Medical and Scientific Officer at Harmony Biosciences, emphasized the collaboration's significance: "By integrating Beacon's innovative EEG platform into our HBS-301 (搜索) Phase 3 studies, we aim to bring new levels of objectivity and reliability to clinical endpoints in hypersomnia disorders, enhancing our ability to evaluate treatment benefit and better serve the patient community."
The partnership reinforces both organizations' shared mission to advance precision medicine in sleep disorders using cutting-edge neurotechnology and clinical research innovation. Harmony Biosciences is a commercial-stage pharmaceutical company with an FDA-approved treatment for narcolepsy (搜索) and a pipeline focused on advancing therapies for sleep/wake, epilepsy, and other rare neurological disorders.